- Optimi Health aims to become a global leader in GMP-certified psilocybin and functional mushroom products to cater to the emerging psychedelic segment of the wellness industry.
- Three revenue streams are in the works to fully capitalize on the diverse needs of the growing market: Optimi Labs, Optimi Farms and Optimi Products. Optimi Products is already generating revenue, while Optimi Farms is slated to become the primary revenue driver.
- The company’s first GMP-certified manufacturing facility will open in May 2022 and can produce 2,000 kilograms of high-quality mushroom products per month. Health Canada has licensed the facility. The new facility will support all three revenue streams.
- An experienced management team leads Optimi Health with expertise in corporate finance, operational excellence, and various scientific disciplines.
It pays to be healthy, depending on how you invest your money. The global wellness industry has already reached US$4 trillion annually, highlighting the massive demand for non-traditional health and wellness products. Psychedelics are emerging as a promising segment of this industry. Psilocybin, famous for its role in “magic mushrooms” is already projected to reach a portion of the US$10.75 billion psychedelic market by 2027. While plenty of hurdles remain to be overcome, psilocybin leads the psychedelic charge towards a new era of wellness.
Why psilocybin? Studies have already shown that the psychedelic compound and its mushrooms have both mental health and nutritional benefits. For example, one study found that psilocybin treatment for major depression is effective for up to a year. Another study indicated effectiveness in treating alcohol abuse. However, legal and regulatory hurdles remain even with solid science backing it. According to the Canadian government, one such hurdle is that mushrooms and their chemical isolates must live up to the standards of Good Manufacturing Practices (GMP). Pioneers who leap over these hurdles position themselves to capitalize on the emerging market.Optimi Health (CSE:OPTI,OTC:OPTHF,FRA:8BN) aims to become the leading global supplier of GMP-grade psilocybin and functional mushrooms for health and wellness markets. The company is already positioning itself as a supplier of scalable natural mushroom formulations to provide transformative experiences for patients. In addition, the company is positioning itself to capitalize on the projected 6.41 percent market growth by 2026 for the psychedelic mushroom market.